<DOC>
	<DOCNO>NCT00001995</DOCNO>
	<brief_summary>To determine drug regimen contain rifabutin eradicate decrease number Mycobacterium avium complex ( MAC ) organisms blood , improve symptom associate MAC infection , increase survival patient AIDS . To assess safety drug regimen .</brief_summary>
	<brief_title>A Double-Blind Randomized Clinical Trial Rifabutin Regimen Treatment Mycobacterium-Avium Complex ( MAC ) Bacteremia Patients With AIDS</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) . Didanosine ( ddI ) . Patients must follow : Diagnosis AIDS define CDC . Blood culture positive Mycobacterium avium complex acidfast bacillus ( AFB ) . Provide write informed consent . Prior Medication : Allowed : If receive zidovudine ( AZT ) ddI must take medication least 4 week prior study entry . Required : Antipneumocystis prophylactic therapy least 4 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Known hypersensitivity study drug . Concurrent Medication : Excluded : Other therapy mycobacterial disease . Patients follow excluded : Known hypersensitivity study drug . Prior Medication : Excluded within 4 week : Therapy mycobacterial disease . Antiretroviral drug , zidovudine ( AZT ) ddI . Investigational drug , ddI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1992</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>